Alpha Family Trust Invests $221,000 in Illumina, Inc. (NASDAQ:ILMN)

Alpha Family Trust bought a new position in Illumina, Inc. (NASDAQ:ILMN) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor bought 1,695 shares of the life sciences company’s stock, valued at approximately $221,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ILMN. Primecap Management Co. CA grew its position in shares of Illumina by 462.5% in the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock worth $253,514,000 after buying an additional 1,997,010 shares during the period. Millennium Management LLC grew its position in shares of Illumina by 305.0% in the 2nd quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock worth $155,067,000 after buying an additional 1,118,747 shares during the period. Capital World Investors grew its position in shares of Illumina by 41.1% in the 1st quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock worth $378,111,000 after buying an additional 801,814 shares during the period. Marshall Wace LLP purchased a new stake in shares of Illumina in the 2nd quarter worth about $77,628,000. Finally, Swedbank AB purchased a new stake in shares of Illumina in the 1st quarter worth about $99,682,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ILMN has been the topic of a number of analyst reports. StockNews.com initiated coverage on shares of Illumina in a research note on Thursday, August 29th. They issued a “buy” rating on the stock. Scotiabank dropped their price target on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research note on Thursday, August 15th. TD Cowen upped their price target on shares of Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. upped their price target on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Finally, Daiwa Capital Markets upgraded shares of Illumina from a “neutral” rating to a “buy” rating and upped their price target for the stock from $120.00 to $154.00 in a research note on Friday, August 16th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Illumina presently has a consensus rating of “Moderate Buy” and an average price target of $164.00.

Illumina Trading Down 5.1 %

Shares of NASDAQ:ILMN opened at $135.05 on Friday. The firm’s 50 day moving average price is $139.66 and its 200-day moving average price is $124.31. Illumina, Inc. has a twelve month low of $92.69 and a twelve month high of $156.66. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.33 EPS. Research analysts predict that Illumina, Inc. will post 4.11 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.